Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epacadostat - Incyte Corporation

Drug Profile

Epacadostat - Incyte Corporation

Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Aduro BioTech; Bristol-Myers Squibb; Columbia University; IMV; Incyte Corporation; MedImmune; Merck AG; Merck Sharp & Dohme; National Cancer Institute (USA); Sidney Kimmel Cancer Center; Stanford University; Washington University School of Medicine
  • Class Antineoplastics; Halogenated hydrocarbons; Nitroso compounds; Oxadiazoles; Small molecules; Sulfonamides
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours
  • Phase I/II Cancer; Colorectal cancer; Prostate cancer
  • No development reported Rectal cancer

Most Recent Events

  • 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
  • 02 Jun 2023 Pharmacokinetics data from a phase I trial in Non small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 14 May 2023 Incyte Corporation completes a phase I/II ECHO 206 trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain and the UK (EudraCT2016-004289-25)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top